Evolution of Chronic Inflammatory Skin Diseases (EPICA)
monocentric retrospective-prospective observational study evaluating the clinical evolution of common chronic inflammatory skin diseases, including atopic dermatitis, psoriasis, prurigo nodularis, chronic hand eczema, and hidradenitis suppurativa. The study will collect demographic, clinical, therapeutic, and validated clinimetric data from patients aged ≥12 years. Its primary aim is to describe changes in disease severity over time. Secondary objectives include identifying demographic, clinical, and treatment-related predictors of moderate-to-severe disease and unfavorable outcomes. Data will cover a 7-year retrospective period and a 10-year prospective follow-up.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Ketty Peris
- 電話番号:+390630155701
- メール:ketty.peris@policlinicogemelli.it
研究場所
-
-
-
Rome、イタリア、00168
- 募集
- Fondazione Policlinico Agostino Gemelli IRCCS
-
コンタクト:
- Ketty Peris, Prof
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
patients affected with inflammatory skin conditions including atopic dermatitis, prurigo nodularis, Hidradenitis suppurativa, psoriasis
説明
Inclusion Criteria:
- Age ≥12 years.
- Patients with a confirmed clinical diagnosis of atopic dermatitis (AD), prurigo nodularis (PN), psoriasis (PSO), chronic hand eczema (CHE), or hidradenitis suppurativa (HS) attending the dermatology outpatient clinics of Fondazione Policlinico Universitario A. Gemelli IRCCS.
- Availability of clinical data at baseline and at subsequent follow-up visits performed according to routine clinical practice.
Exclusion Criteria:
- Age <12 years; absence of the minimum required data (treatment start date and at least one follow-up visit with a clinical score).
- Refusal or inability to understand and sign the informed consent form.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change Over Time in Eczema Area and Severity Index (EASI)
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Eczema Area and Severity Index (EASI) in participants with atopic dermatitis. EASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in SCORing Atopic Dermatitis (SCORAD)
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in SCORing Atopic Dermatitis (SCORAD) in participants with atopic dermatitis. SCORAD ranges from 0 to 103, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Patient-Oriented Eczema Measure (POEM)
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Patient-Oriented Eczema Measure (POEM) in participants with atopic dermatitis. POEM ranges from 0 to 28, with higher scores indicating greater patient-reported disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Psoriasis Area and Severity Index (PASI)
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Psoriasis Area and Severity Index (PASI) in participants with psoriasis. PASI ranges from 0 to 72, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hand Eczema Severity Index (HECSI)
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Hand Eczema Severity Index (HECSI) in participants with chronic hand eczema. HECSI ranges from 0 to 360, with higher scores indicating greater disease severity. |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Investigator's Global Assessment for Prurigo Nodularis
時間枠:Baseline and every 16 ± 4 weeks, up to 120 months
|
Change in Investigator Global Assessment (IGA) in patients with prurigo nodularis |
Baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Itch Numerical Rating Scale (NRS)
時間枠:baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in itch intensity assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, where 0 indicates no itch and 10 indicates the worst imaginable itch. Higher scores indicate worse itch. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Sleep Numerical Rating Scale (NRS)
時間枠:baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in sleep disturbance assessed using the Numerical Rating Scale (NRS). Scores range from 0 to 10, with higher scores indicating greater sleep disturbance. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Dermatology Life Quality Index (DLQI)
時間枠:baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in Dermatology Life Quality Index (DLQI). Scores range from 0 to 30, with higher scores indicating greater impairment in dermatology-related quality of life. |
baseline and every 16 ± 4 weeks, up to 120 months
|
|
Change Over Time in Hurley Stage
時間枠:baseline and every 16 ± 4 weeks, up to 120 months
|
Change over time in hidradenitis suppurativa severity according to Hurley staging. Hurley stage ranges from Stage I to Stage III, with higher stages indicating more severe disease. |
baseline and every 16 ± 4 weeks, up to 120 months
|
協力者と研究者
捜査官
- 主任研究者:Ketty Peris、Fondazione Policlinico Universitario Agostino Gemelli IRCCS
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 27085
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。